TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 2.30nMAssay Description:Inhibition of [3H]AVP binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 23nMAssay Description:Inhibition of 1 nM AVP-induced cAMP accumulation in cells expressing human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 44nMAssay Description:Inhibition of [3H]AVP binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 90nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 6.00E+3nMAssay Description:Inhibition of 1 nM AVP-induced calcium mobilisation in cells expressing human vasopressin V1a receptorMore data for this Ligand-Target Pair